7:00 am Concert Pharmaceuticals has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis (CNCE) : The first Phase 1 trial will be a crossover study to compare two proprietary deuterium-modified compounds in order to select one for further clinical evaluation. The Phase 1 program also encompasses single- and multiple-ascending doses to further evaluate the safety and pharmacokinetics of the selected candidate.
The final phase of the Phase 1 program will assess multiple ascending doses of the selected compound compared to placebo and is expected to begin in the second half of 2015. The Company expects to report top-line data upon completion of the multiple dose Phase 1 program.
If you were to reduce your position in VRTX, what other stocks do you hold or find interesting? I have held since Aurora, also, but may have to diversify holdings since VRTX holds too high a percentage of assets. Sorry to use the board to talk about other stocks, but trust the expertise here.